News articles about Novan (NASDAQ:NOVN) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novan earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9156217135201 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
NOVN has been the topic of several recent research reports. ValuEngine lowered shares of Novan from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Piper Jaffray Companies reiterated a “buy” rating on shares of Novan in a research report on Thursday, August 3rd. Finally, Zacks Investment Research cut shares of Novan from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $14.69.
Novan (NASDAQ:NOVN) opened at 3.99 on Friday. Novan has a 1-year low of $3.52 and a 1-year high of $30.90. The company’s market capitalization is $63.78 million. The firm has a 50 day moving average of $4.28 and a 200-day moving average of $5.02.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.com-unik.info/2017/08/19/novan-nasdaqnovn-getting-somewhat-positive-news-coverage-report-shows-updated.html.
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
What are top analysts saying about Novan Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novan Inc and related companies.